Nasdaq accepts nls pharmaceutics' plan to regain listing compliance

Zurich, switzerland / accesswire / march 11, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has been notified by the listing qualifications department of the nasdaq stock market llc ("nasdaq") that the company's plan to regain compliance submitted on february 23, 2024 has been approved.
NLSP Ratings Summary
NLSP Quant Ranking